Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

By V. McLaughlin, R. Oudiz, A. Frost, V. Tapson, S. Murali, R. Channick, D. Badesch, R. Barst, H. Hsu, L. Rubin. American Journal of Respiratory and Critical Care Medicine, 2006

636 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a4fc82959a38fb6683fd0108d21dc395edb64127

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, background): “Hospitalization for worsening pulmonary arterial hypertension 10 (4) 30 (12) 18 (14) 12 (10)”
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008, background): “Sex, n (%) Men 30 (23) 24 (18) Women 103 (77) 110 (82)”
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 (2008, neutral): “Connective tissue disease 21 (31) 19 (28) 22 (33) 22 (34) 19 (30) 21 (33)”